Pharmacovigilance

(001) Evaluation Of The Potential Rebound Effect Of Denosumab Discontinuation: A Comparative Study Of Five Different Types Of Antiosteoporotic Medications

(002) Challenges and future perspectives of enhanced passive safety surveillance (EPSS) of influenza vaccines in Europe

(003) Clinical Harms Associated with Xylazine Use in Humans

(004) Mapping the Information Pathways of Adverse Reactions Through Clinical Event Sequences, Patient Interactions with the Healthcare System and Generation of Different Data Streams – a Qualitative Pilot Study

(005) A Real-world Evidence on Electrolyte Disorders with Piperacillin/Tazobactams :Using the FARES Database over 10 years

(006) Trends and Patterns of the Reported Antimicrobial Errors to the Eastern Region’s Medical Centers in Saudi Arabia: A Cross-Sectional Study

(007) Characterization of Japanese Risk Management Plans Using Automatically Extracted Information by Robotic Process Automation Tool

(008) Hypersensitivity Reactions with Ultrasound Contrast Agents in Patients with a History of Polyethylene Glycol Allergy

(009) Pharmacovigilance of pharmaceutical products in colorectal cancer: a systematic review and metanalysis

(010) Comparing the Efficacy and Safety of Dolutegravir and Efavirenz-based Antiretroviral Regimens: A Retrospective Study

(011) Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: a cohort study

(012) Safety of using nirmatrelvir/ritonavir and cardiovascular medications with potential drug-drug interactions: Comparative safety analysis using WHO international database

(013) Risk of gastrointestinal bleeding associated with antiviral treatment among influenza patients

(014) Association between use of fluoroquinolones and risk of mitral or aortic valve regurgitation: a population-based cohort study

(015) In-utero azathioprine exposure and neurodevelopmental disorders in the offspring

(016) Cardiovascular Adverse Events associated with JAK Inhibitor versus TNF Inhibitor: A Disproportionality Analysis in National Pharmacovigilance Database of Korea

(017) Cohort Study of Serious Angioedema in Association with Sacubitril/Valsartan Use in Black Patients with Heart Failure

(018) Interaction Between Cannabis And Cytochromes P450 Substrates: Potential Safety Signals from a Disproportionality Analysis Using the US Food And Drug Administration Adverse Event Reporting System Database

(019) A new tool to estimate comorbidities at the population-level in the United States

(020) Association between Cumulative Corticosteroid Dose and Risk of Avascular Necrosis in patients with Systemic Lupus Erythematosus : A nested case-control study

(021) Aspirin and non-aspirin antiplatelet agents use and risk of ischemic and hemorrhagic stroke in patients with non-valvular atrial fibrillation with and without anticoagulant therapy: a case-referent study

(022) Temporal Trends in Adverse Drug Reactions Reports of Medicines for Treating Human Immunodeficiency Virus and Tuberculosis, and All Diseases: Joinpoint Regression

(023) The Impact of the Removal of Liver Injury Warning and Liver Testing Requirement on Ambrisentan Use and Liver Function Testing

(025) Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022

(026) Adverse Drug Reaction Reporting Among Nurses in Nigeria: Opinion Survey of Their Knowledge, Attitude, and Practice

(027) Factors linked to hospital-admission of chronic non-cancer pain patients prescribed long-term strong opioids

(028) Development and Implementation of the National Clozapine Safety System for the Department of Veterans Affairs

(029) Characterizing of adverse events across 30,000 peer reviewed case report publications

(030) Development and validation of technology assisted tool for Data mining of public version of FAERS database using python language

(031) Medical Scandal with illegally diluted Chemotherapy in Germany: Prognosis of Patients with Breast and non-solid Cancers

(032) Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018- July 1, 2022

(033) Prescription Sequence Symmetry Analysis of Administrative Claims Data for Detection of Opioid Use Adverse Events

(034) Relationship Between Misuse of Substances and Abuse as Reported in the FDA FAERS data

(035) Medication Safety Stewardship in Antibiotic usage in Critical Care Units

(036) Physician Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies: Results from a National Survey

(037) Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in non-small cell lung cancer patients receiving first-line treatment

(038) Risk of Cholelithiasis and Cholecystitis for antidiabetic medications: Evidence synthesis from a disproportionality analysis

(039) RAAS Inhibitors-Related Adverse Drug Reactions and the Risk of Subsequent Cardiovascular Event and All-Cause Mortality: A Cohort Study in UK Primary Care

(040) Bleeding related adverse events associated with antiviral treatment in influenza patients: a disproportionality analysis using FDA adverse event reporting system (FAERS)

(041) Budsinfo: A User-Friendly Platform for Reporting the Effects of Cannabis and Hemp-Derived Products

(042) Laboratory screening tests before and during the use of systemic immunomodulatory agents in patients with chronic inflammatory skin diseases

(043) Health Canada’s Vigilance Framework for Cannabis: A summary of adverse reactions associated with cannabis products

(044) Open insurance claims database vs closed insurance claims database to support pharmacovigilance review of potential safety event in patients with B-cell malignancies: a fit for purpose evaluation

(045) Impact of European Union label changes to avoid inadvertent use of once-weekly methotrexate: A cross-sectional survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour

(046) Extent of apremilast exposure misclassification in CPRD Aurum: a validation study

(047) Technology Aided Intervention to Improve the Metabolic Monitoring Rate in Patients on Atypical Antipsychotics

(048) Quality compliance while conducting NIS studies: critical success factors assessment and the use of key performance indicators

(049) Poisonings with Antidepressants in Relation to Prescriptions; Venlafaxine and Amitriptyline Stands Out

(050) A Qualitative Approach in Assessing the Contributing Factors towards the Medication Error-Prone Behavior amongst the Healthcare Professionals

(051) Monitoring of adverse events during seasonal malaria chemoprevention campaigns in children aged 3-59 months in Burkina Faso: A real-world evidence

(052) Initiation and Implementation of a Medication Error Reporting and Monitoring Program: A Developing Country Scenario

(053) Proton pump inhibitors and risk of kidney diseases: An overview of meta-analyses

(054) Supporting pharmacovigilance signal validation and prioritisation with analyses of routinely collected health data – lessons learned from an EHDEN network study

(055) Psychological and Neurological Adverse Drug Events Associated with Direct Acting Antivirals Agents Used for Hepatitis C Virus: Analysis and Comparison of the FDA Adverse Event Reporting System (FAERS) and Lexicomp

(056) A Novice Stratagem in the Quantification of the Contributing Factors Associated to Medication Errors

(058) Impact of Educational Awareness on Knowledge and Attitude of ADR Reporting Among Medical, Pharmacy, Dentistry and Nursing Students: An Interventional Study

(059) Classifying Chemotherapy Chaos: Navigating Blood & Lymphatic Side Effects

(060) Rapid Use of Real-World Data in Safety Signal Assessment

(062) Fatal tramadol intoxications in Sweden, almost 50% of the individuals lacked a prescription

(063) Causality assessment of adverse drug reactions in post-authorization settings: An analysis from four different countries to find out the most comprehensive and easy-to-use tool

(064) Capecitabine-Induced Adverse Reactions in Patients with Biliary Tract Cancer: Evidence from Spontaneous Reporting Data Analysis and Systematic Review & Meta-Analysis

(065) Potential Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions(DDIs) of QT Prolonging Drugs in a cohort of Psychiatry Patients

(067) Uncovering the Skin Reactions: Retrospectively Analyzing the Adverse Drug Reactions Related to Skin & Subcutaneous Tissues disorders

(068) Descriptive Analysis of Safety of Ketamine Utilizing FDA Adverse Events Reporting System FAERS Database

(069) Sociodemographic Factors Affecting Drug Interactions in Stable Angina Pectoris Patients in the Cardiology Polyclinic of A Tertiary General Hospital in Banjarmasin

(070) Application of machine learning methods in risk assessment of fracture associated with antihypertensives in older people with a large number of confounders

(071) Drug Plan Monitoring of Paxlovid Adherence and Patient-Reported Adverse Events in British Columbia

(072) Association between Mortality and Cumulative Exposure to Antipsychotics, Antidepressants and Benzodiazepines in Patients with Schizophrenia: A Real-World Observational Study

(073) Purine antimetabolites associated pneumocystis jiroveci pneumonia among autoimmune and cancer population

(074) Active and Passive Safety Surveillance in Children Receiving Live Attenuated Influenza Vaccine (LAIV), in England During Early Influenza Seasons from 2014/2015 to 2021/2022

(075) Reasons for Treatment Alteration in Dermatology Patients: Insights from Unstructured Clinical Notes

(076) Drug Repurposing for Hepatocellular Carcinoma via Real World Data Corroborated with Bioinformatics

(077) A Canadian Approach to Classifying Acute Kidney Injury and Other Reports of Renal Adverse Events of Interest Following Immunization

(078) Perception of Facilitators and Barriers to Strengthen restriction of non-medical use opioid prescription among healthcare practitioner in China: a qualitative study

(079) Graph Machine Learning in Adverse Events Safety Signal Management: A Research Proposal

(080) Identification of a novel signal congenital scoliosis for zopiclone through FDA FAERS database

(081) Active surveillance and evaluation of anosmia/ageusia following mRNA-1273 administration: Learnings from a US administrative claims database study